[Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis]
- PMID: 9011880
- DOI: 10.1590/s0037-86821996000600005
[Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis]
Abstract
From September to November 1994. 21 patients with active mucosal leishmaniasis were treated with aminosidine sulphate 16 mg/kg/day by intramuscular injection for 20 days. They were principally adult male agricultural workers. Thirteen patients had not received specific treatment and eight had failed to respond to Glucantime therapy. Diagnosis was based on clinical and epidemiological observations, a search for the parasite, leishmanin skin sensitivity and indirect fluorescent antibody serological tests. Sixty seven percent of patients had leishmania parasites isolated from inoculated hamsters or visualized in imprints or histopathological sections. The mean follow-up period was 12.6 months. All patients completed treatment. Side effects were pain at the injection site (86%); mild proteinuria (24%), elevated serum creatinine (.5%) and subclinical bearing loss in one of two patients who did audiometric tests. Clinical cure was achieved in 48% and the accumulated relapse rate was 29% (4/14).
Similar articles
-
[Aminosidine in the treatment of mucocutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis].Rev Soc Bras Med Trop. 1996 Mar-Apr;29(2):215-6. doi: 10.1590/s0037-86821996000200014. Rev Soc Bras Med Trop. 1996. PMID: 8713613 Portuguese. No abstract available.
-
[Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].Acta Cient Venez. 1984;35(5-6):394-403. Acta Cient Venez. 1984. PMID: 6537698 Spanish. No abstract available.
-
[Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis].Rev Soc Bras Med Trop. 1996 Sep-Oct;29(5):447-53. doi: 10.1590/s0037-86821996000500007. Rev Soc Bras Med Trop. 1996. PMID: 8966308 Clinical Trial. Portuguese.
-
Mucosal leishmaniasis ("espundia" Escomel, 1911).Trans R Soc Trop Med Hyg. 1986;80(6):859-76. doi: 10.1016/0035-9203(86)90243-9. Trans R Soc Trop Med Hyg. 1986. PMID: 3037735 Review.
-
Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report.Mem Inst Oswaldo Cruz. 1992 Oct-Dec;87(4):487-92. doi: 10.1590/s0074-02761992000400005. Mem Inst Oswaldo Cruz. 1992. PMID: 1343662 Review.
Cited by
-
Triphenylmethane derivatives have high in vitro and in vivo activity against the main causative agents of cutaneous leishmaniasis.PLoS One. 2013;8(1):e51864. doi: 10.1371/journal.pone.0051864. Epub 2013 Jan 14. PLoS One. 2013. PMID: 23341885 Free PMC article.
-
Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Drugs. 2013 Nov;73(17):1889-920. doi: 10.1007/s40265-013-0132-1. Drugs. 2013. PMID: 24170665 Review.
-
The cure rate after different treatments for mucosal leishmaniasis in the Americas: A systematic review.PLoS Negl Trop Dis. 2022 Nov 17;16(11):e0010931. doi: 10.1371/journal.pntd.0010931. eCollection 2022 Nov. PLoS Negl Trop Dis. 2022. PMID: 36395328 Free PMC article.
-
An update on pharmacotherapy for leishmaniasis.Expert Opin Pharmacother. 2015 Feb;16(2):237-52. doi: 10.1517/14656566.2015.973850. Epub 2014 Oct 25. Expert Opin Pharmacother. 2015. PMID: 25346016 Free PMC article. Review.